Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | KIF11 | P52732 | 9/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879465 | 1.00 | CA4 (0.54) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL1286989 | 0.82 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL14856630 | 0.82 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL8858901 | 0.82 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL10112758 | 0.82 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL5051055 | 0.82 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL8648265 | 0.82 | CA4 (0.59) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL7021665 | 0.80 | CA4 (0.56) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL4570566 | 0.80 | CA4 (0.56) | CA4LTA4HKIF11KCNH2CA12 | |
| SCHEMBL6787449 | 0.80 | CA4 (0.56) | CA4LTA4HKIF11KCNH2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
| JP-2005255528-A | NEW CARBONIC ACID ESTER DERIVATIVE AND METHOD FOR SYNTHESIZING NUCLEIC ACID BY UTILIZING THE SAME | JAPAN SCIENCE & TECHNOLOGY AGENCY | 2005-09-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, DUT, ADAR | CA4 1123/4885LTA4H 2365/4885KIF11 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.